Compare IDEXX Laboratories, Inc. (IDXX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Yum China Holdings Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while Yum China Holdings Inc trades at $47.71 (market cap $16.28B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.8× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays a 2.44% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | YUMC | |
|---|---|---|
Market Cap | $46.22B | $16.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $57.95 |
52-Week Low | $526.44 | $40.18 |
Enterprise Value | $47.12B | $17.19B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
YUMC trades at $47.92, down 0.56% on the day, with a bullish technical signal supported by moving averages. The company demonstrates consistent fundamental strength with Q2 2026 earnings beating estimates, revenue growth of 13% year-over-year, and a net income margin of 7.84%. Recent completion of the Pizza Hut China acquisition for $1.2 billion positions the company for strategic growth and cost synergies.
The outlook remains positive with strong analyst support (73.68% buy ratings) and a 26.21% upside potential. Key risks include Chinese macroeconomic headwinds and integration challenges from the Pizza Hut acquisition. Earnings momentum and valuation metrics suggest continued growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
